Fig. 3. Targeting RPL9 inhibits the growth of CR-CSCs via disruption of ID-1 signaling axis. (A) Inhibition of growth of CD133⁺ HT29 CSCs by RPL9 silencing. (B) Reduction of CD133 and ID-1 mRNA expression in RPL9-silenced CD133⁺ HT29 CSCs. (C) Reduction of CD133, ID-1, and p-IκBα proteins in RPL9-silenced CD133⁺ HT29 CSCs. β-Actin was used as a loading control. ***P < 0.001 vs. NC siRNA treatment. RPL9, ribosomal protein L9; CR-CSC, colorectal cancer stem cell; ID-1, inhibitor of DNA-binding 1; NC, negative control.

© J Cancer Prev